We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+0.63%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$911M
AUM Growth
-$128M
Cap. Flow
-$82.6M
Cap. Flow %
-9.07%
Top 10 Hldgs %
73.8%
Holding
28
New
5
Increased
6
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$44.1M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$38M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$30.7M
4
MYGN icon
Myriad Genetics
MYGN
+$26.8M
5
NVDQ
Novadaq Technologies Inc.
NVDQ
+$21.9M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$61.9M
2
AKRX
Akorn Inc
AKRX
+$60M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$52.3M
4
UTHR icon
United Therapeutics
UTHR
+$30.4M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.96%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
$121M 13.32%
2,730,887
-800,600
-23% -$28.2M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$93.7M 10.3%
5,793,903
+2,095,000
+57% +$38M
UTHR icon
3
United Therapeutics
UTHR
$26.2B
$83.3M 9.15%
580,701
-237,999
-29% -$30.4M
AMRN
4
Amarin Corp
AMRN
$298M
$77.2M 8.47%
1,252,619
+20,000
+2% +$1.27M
MNK
5
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$57.5M 6.31%
1,153,944
-406,213
-26% -$23.9M
TVTX icon
6
Travere Therapeutics
TVTX
$5.33B
$52.5M 5.76%
2,772,156
-312,791
-10% -$6.4M
ATRC icon
7
AtriCure
ATRC
$2.04B
$52.2M 5.73%
2,666,354
+2,434,428
+1,050% +$44.1M
GMED icon
8
Globus Medical
GMED
$10.9B
$46.2M 5.07%
1,860,000
– –
ARIA
9
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$44.2M 4.86%
3,553,943
-5,141,799
-59% -$61.9M
MD icon
10
Pediatrix Medical
MD
$2.17B
$44M 4.83%
660,000
– –
MYGN icon
11
Myriad Genetics
MYGN
$507M
$38.8M 4.26%
2,328,932
+1,478,932
+174% +$26.8M
MACK
12
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$37M 4.06%
1,152,543
+396,269
+52% +$16.9M
AMAG
13
DELISTED
AMAG Pharmaceuticals
AMAG
$35.7M 3.92%
+1,026,902
New +$30.7M
ANIP icon
14
ANI Pharmaceuticals
ANIP
$1.83B
$29.8M 3.27%
491,608
-161,650
-25% -$9.88M
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
$23.9M 2.63%
+2,723,471
New +$20M
PCRX icon
16
Pacira BioSciences
PCRX
$1.06B
$20.4M 2.24%
+631,805
New +$21.1M
NVDQ
17
DELISTED
Novadaq Technologies Inc.
NVDQ
$17.1M 1.88%
+2,413,179
New +$21.9M
ACHC icon
18
Acadia Healthcare
ACHC
$2.62B
$16.9M 1.86%
+510,666
New +$19.8M
VCEL icon
19
Vericel Corp
VCEL
$2.43B
$8.95M 0.98%
2,982,940
+750,000
+34% +$1.93M
ADMA icon
20
ADMA Biologics
ADMA
$2.01B
$6.52M 0.72%
1,273,933
– –
BIOL
21
DELISTED
Biolase, Inc.
BIOL
$2.03M 0.22%
116
-27
-19% -$534K
SPNE
22
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$1.01M 0.11%
128,127
-134,807
-51% -$1.14M
VCYT icon
23
Veracyte
VCYT
$4.77B
$362K 0.04%
46,752
-119,073
-72% -$891K
EHTH icon
24
eHealth
EHTH
$43.8M
– –
-1,154,711
Closed -$12.9M
HSTM icon
25
HealthStream
HSTM
$824M
– –
-340,847
Closed -$9.41M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Consonance Capital Management held 28 positions worth $911M, down 12% from $1.04B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Consonance Capital Management withdrew a net $82.6M in Q4 2016, closing 5 positions and reducing 9 holdings. Its most notable exit was Akorn Inc, an estimated $60M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, Consonance Capital Management opened a new position in AMAG Pharmaceuticals worth $35.7M.

  • Consonance Capital Management's largest Q4 2016 buy was AMAG Pharmaceuticals: 1,026,902 shares worth $35.7M.
  • Consonance Capital Management added most to AtriCure in Q4 2016, an estimated $44.1M increase.
  • Consonance Capital Management's biggest Q4 2016 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $61.9M.
  • Consonance Capital Management fully exited Akorn Inc in Q4 2016, selling an estimated $60M.
  • Consonance Capital Management's ten largest holdings make up 74% of its $911M portfolio in Q4 2016.
  • Consonance Capital Management opened 5 new positions and closed 5 in Q4 2016.
  • Consonance Capital Management's portfolio value fell 12% quarter-over-quarter to $911M.

Based on Consonance Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.